(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

KESIMPTA

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

KESIMPTA

ST13

US500000079227649

Class

5

Filing

79227649

Registration

5537963

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

28

Latest update

12/26/2025

Trademark type

Word

Nice classes

5

Filing date

01/15/2018

Registration date

08/14/2018

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

10/09/2024

Last transaction

12/26/2025

Responsible office

United States Patent and Trademark Office

Status code

706

Official register

Principal Register

Drawing code

4

Owner type

25

Owner location

Basel, CH

Examiner

SAUNDERS,ANDREA DAWN

Current location

Historical data usage

Holders and representatives

Holders

Novartis AG
Novartis AG

Representatives

Maury M. Tepper, III Tepper & Eyster, PLLC

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system ; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculoskeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Publications

History of USPTO decisions and trademark events.

28 publications found

INNP

PARTIAL INVALIDATION PROCESSED BY THE IB

12/25/2025

INPS

PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB

11/07/2025

INPC

INVALIDATION PROCESSED

11/07/2025

NA15

SEC. 15 ACKNOWLEDGEMENT - E-MAILED

10/18/2025

15AK

REGISTERED - SEC. 15 ACKNOWLEDGED

10/18/2025

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

10/18/2025

E15R

TEAS SECTION 15 RECEIVED

10/06/2025

INPR

PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED

06/09/2025

NA71

NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED

10/09/2024

71AG

REGISTERED-SEC.71 ACCEPTED

10/09/2024

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

10/07/2024

ES71

TEAS SECTION 71 RECEIVED

02/09/2024

GPNX

NOTIFICATION PROCESSED BY IB

10/12/2018

FICS

FINAL DISPOSITION NOTICE SENT TO IB

09/21/2018

FIMP

FINAL DISPOSITION PROCESSED

09/21/2018

GPAR

GRANT OF PROTECTION CREATED, TO BE SENT TO IB

09/13/2018

R.PR

REGISTERED-PRINCIPAL REGISTER

08/14/2018

GPNX

NOTIFICATION PROCESSED BY IB

06/02/2018

PUBO

PUBLISHED FOR OPPOSITION

05/29/2018

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

05/16/2018

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

05/16/2018

NPUB

NOTICE OF PUBLICATION

05/09/2018

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

04/26/2018

DOCK

ASSIGNED TO EXAMINER

04/25/2018

MAFR

APPLICATION FILING RECEIPT MAILED

03/13/2018

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

03/08/2018

LIMI

LIMITATION FROM ORIGINAL APPLICATION ENTERED

03/07/2018

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

03/01/2018

Continuous trademark protection

Get notified about every new filing that threatens KESIMPTA or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.